Option Care Health, CooperCompanies, Neogen, GoodRx, and Fortrea Shares Are Falling, What You Need To Know

What Happened?

A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses. 

According to the Bureau of Labor Statistics, the economy lost 92,000 nonfarm payroll jobs, a stark reversal from the 50,000 gain that was anticipated by economists. The healthcare sector, typically a consistent source of job growth, shed 28,000 positions. This disappointing data has raised investor concerns about a potential economic slowdown, which could lead to reduced healthcare spending and demand for services, contributing to the sector's decline in the market.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

• Senior Health, Home Health & Hospice company Option Care Health (NASDAQ:OPCH) fell 3.7%. Is now the time to buy Option Care Health? Access our full analysis report here, it’s free.
• Medical Devices & Supplies - Diversified company CooperCompanies (NASDAQ:COO) fell 3.5%. Is now the time to buy CooperCompanies? Access our full analysis report here, it’s free.
• Medical Devices & Supplies - Diversified company Neogen (NASDAQ:NEOG) fell 6.9%. Is now the time to buy Neogen? Access our full analysis report here, it’s free.
• Healthcare Technology for Patients company GoodRx (NASDAQ:GDRX) fell 4.8%. Is now the time to buy GoodRx? Access our full analysis report here, it’s free.
• Drug Development Inputs & Services company Fortrea (NASDAQ:FTRE) fell 3.3%. Is now the time to buy Fortrea? Access our full analysis report here, it’s free.

Zooming In On Neogen (NEOG)

Neogen’s shares are extremely volatile and have had 39 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was about 2 months ago when the stock gained 27.6% on the news that the company reported fourth-quarter results that far surpassed Wall Street's expectations and raised its financial forecast for the full year. 

The life sciences company posted adjusted earnings per share of $0.10, easily beating the analyst consensus of $0.07. Revenue for the quarter came in at $224.7 million, also topping the anticipated $209.7 million. Despite sales falling 2.8% year on year, investors were encouraged by the significant beats on both the top and bottom lines. Looking ahead, Neogen raised its full-year revenue guidance to a midpoint of $850 million, ahead of Wall Street estimates. The company also increased its outlook for adjusted EBITDA to approximately $175 million, signaling confidence in its future performance.

Neogen is up 40.2% since the beginning of the year, but at $9.82 per share, it is still trading 13.4% below its 52-week high of $11.33 from February 2026. Investors who bought $1,000 worth of Neogen’s shares 5 years ago would now be looking at an investment worth $247.42.

ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.

These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.